Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and ...

US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Palliative care is not just about medicines to control symptoms. Cancer treatments can also reduce or get rid of symptoms. For example, they can help to reduce pain by shrinking a tumour and reducing ...

Dying from colon cancer in the end stage means that treatments are no longer working or need to be stopped due to side effects. The cancer has spread throughout the body, and the condition is ...

Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Shanghai 200080, China Department of Gastric Surgery, Cancer Hospital of ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Pathogenic variants were then studied in vivo using a transgenic zebrafish model. Conclusions Our study highlights the specific role of BMP/TGF-β and VEGF/VEGFR signalling in the aetiology of BAVM and ...

The development of dual-target inhibitors for VEGFR-2 and c-Met holds promise for more effective cancer therapies that could overcome tumor cell resistance, a limitation often observed with inhibitors ...